ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 156 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2017. The put-call ratio across all filers is 1.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $5,055,000 | +5.1% | 61,500 | 0.0% | 0.45% | -13.7% |
| Q2 2020 | $4,811,000 | +58.0% | 61,500 | -10.3% | 0.52% | +21.8% |
| Q1 2020 | $3,045,000 | -30.9% | 68,524 | -27.9% | 0.43% | -28.2% |
| Q4 2017 | $4,406,000 | -17.3% | 95,000 | -5.0% | 0.60% | -12.5% |
| Q3 2017 | $5,326,000 | +141.1% | 100,000 | +181.1% | 0.68% | +114.5% |
| Q2 2017 | $2,209,000 | +351.7% | 35,573 | +255.7% | 0.32% | +264.4% |
| Q2 2016 | $489,000 | -80.7% | 10,000 | -75.0% | 0.09% | -82.7% |
| Q1 2016 | $2,532,000 | – | 40,000 | – | 0.50% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |